Ray Dalio
KRYS icon

Ray Dalio’s Krystal Biotech KRYS Stock Holding History

Ray Dalio’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Buy
46,367
+36,352
+363% +$9.67M 0.05% 240
2025
Q4 		$2.47M Buy
10,015
+292
+3% +$61.5K 0.01% 719
2025
Q3 		$1.72M Buy
+9,723
New +$1.46M 0.01% 761

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ray Dalio's KRYS Position: Q1 2026 in Review

Ray Dalio increased its Krystal Biotech (KRYS) stake by 363% in Q1 2026, buying an estimated $9.67M and bringing the position to 46,367 shares worth $12M. The position accounts for 0.05% of the portfolio, ranked #240.

Ray Dalio first reported a position in KRYS in Q3 2025 and has held it in 3 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Ray Dalio held 46,367 shares of Krystal Biotech worth $12M as of Q1 2026.
  • Ray Dalio bought 36,352 Krystal Biotech shares in Q1 2026, an estimated $9.67M.
  • Krystal Biotech made up 0.05% of Ray Dalio's portfolio in Q1 2026, its #240 holding.
  • Ray Dalio first reported a position in Krystal Biotech in Q3 2025 and has held it in 3 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.